The DOI matches its Crossref record; 604 of the 604 references it cites were found in a registry or an index.
Central role of mitochondria in drug-induced liver injury
Abstract
A frequent mechanism for drug-induced liver injury (DILI) is the formation of reactive metabolites that trigger hepatitis through direct toxicity or immune reactions. Both events cause mitochondrial membrane disruption. Genetic or acquired factors predispose to metabolite-mediated hepatitis by increasing the formation of the reactive metabolite, decreasing its detoxification, or by the presence of critical human leukocyte antigen molecule(s). In other instances, the parent drug itself triggers mitochondrial membrane disruption or inhibits mitochondrial function through different mechanisms. Drugs can sequester coenzyme A or can inhibit mitochondrial β-oxidation enzymes, the transfer of electrons along the respiratory chain, or adenosine triphosphate (ATP) synthase. Drugs can also destroy mitochondrial DNA, inhibit its replication, decrease mitochondrial transcripts, or hamper mitochondrial protein synthesis. Quite often, a single drug has many different effects on mitochondrial function. A severe impairment of oxidative phosphorylation decreases hepatic ATP, leading to cell dysfunction or necrosis; it can also secondarily inhibit ß-oxidation, thus causing steatosis, and can also inhibit pyruvate catabolism, leading to lactic acidosis. A severe impairment of β-oxidation can cause a fatty liver; further, decreased gluconeogenesis and increased utilization of glucose to compensate for the inability to oxidize fatty acids, together with the mitochondrial toxicity of accumulated free fatty acids and lipid peroxidation products, may impair energy production, possibly leading to coma and death. Susceptibility to parent drug-mediated mitochondrial dysfunction can be increased by factors impairing the removal of the toxic parent compound or by the presence of other medical condition(s) impairing mitochondrial function. New drug molecules should be screened for possible mitochondrial effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, chronic and/or binge alcohol, high fat diets, tobacco smoking, or certain hepatotoxic drugs can directly damage the mitochondrial ETC, producing greater amounts of ROS leaked from the ETS [24], [25], [26], [27].”
Citations
Cites
Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes
Esterbauer, H., Schaur, R. J., & Zollner, H. (1991) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(91)90192-6 · Cited by 6,672
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,197
Mitochondrial formation of reactive oxygen species
Turrens, J. F. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.049478 · Cited by 5,084
Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis
Li, H., Zhu, H., Xu, C.-J., & Yuan, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81590-1 · Cited by 4,445
Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R. C., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80611-x · Cited by 4,139
Circulating mitochondrial DAMPs cause inflammatory responses to injury
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., & Hauser, C. J. (2010) · Nature · doi:10.1038/nature08780 · Cited by 3,812
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317
Urano, F., Wang, X.-Z., Bertolotti, A., Zhang, Y.-H., Chung, P., Harding, H., & Ron, D. (2000) · Science · doi:10.1126/science.287.5453.664 · Cited by 3,081
Roles of CHOP/GADD153 in endoplasmic reticulum stress
Oyadomari, S., & Mori, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401373 · Cited by 2,879
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 1×
“Genetic differences in CYP expression CYP isoenzymes are under genetic control, and hepatic levels of a given isoenzyme differ considerably in different people (Shimada et al., 1994).”
Background
Research works printed but not linked: 33
- Albrecht H., 1995, J Inflamm, 45, 64
- Bedossa P., 1994, Hepatology, 19, 1262
- Brivet F. G., 1999, J Hepatol, 30, 364
- Carini R., 1995, Hepatology, 21, 1089
- Chabrol B., 1994, Eur J Pediatr, 153, 133
- Clarke L., 1989, Cancer Res, 49, 2344
- Cribb A. E., 1996, Adverse Drug React Toxicol Rev, 15, 9
- Curzio M., 1985, Int J Tissue React, 7, 137
- De la Iglesia F. A., 1974, Lab Invest, 4, 539
- Dutertre J. P., 1991, Eur J Gastroenterol Hepatol, 3, 953
- Dybing E., 1976, Mol Pharmacol, 12, 911
- Feigelson H. S., 1997, Cancer Res, 57, 1063
- Feigelson H. S., 1998, Cancer Res, 58, 585
- Grimbert S., 1995, Am J Physiol, 268, G107
- Itoh S., 1977, Acta Hepato-Gastroenterol, 24, 415
- Kent P. D., 2004, J Rheumatol, 31, 1727
- Lettéron P., 1997, Am J Physiol, 272, G1141
- Lillibridge J. H., 1997, Drug Metab Dispos, 24, 509
- Lucena MI, 2011, Gastroenterology
- Moult P. J., 1975, Q J Med, 44, 99
- Nass M. M., 1984, Cancer Res, 44, 2677
- Ohnishi T., 2005, Oncol Rep, 13, 485
- Pessayre D., 1980, Biochem Pharmacol, 29, 219
- Poon G. K., 2001, Drug Metab Dispos, 29, 1608
- 10.1001/jama.1988.03410210079041 · DOI
- Roy S., 1980, Res Commun Chem Pathol Pharmacol, 27, 507
- Susin S A., 1998, Biochim Biophys Acta, 15, 1
- 10.1097/00008571-200303000-00004 · DOI
- Wang M., 1998, Drug Metab Dispos, 26, 98
- Wen B., 2011, Drug Metab Dispos
- Werner S., 1996, Cancer Res, 56, 4391
- Yunis A. A., 1989, Am J Med, 87, N44
- Zhang Z., 1993, Am J Hum Genet, 52, 1111
Cited by
Sorted by citations
Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases
Mansouri, A., Gattolliat, C., & Asselah, T. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.083 · Cited by 839
Self-citationMolecular pathways of nonalcoholic fatty liver disease development and progression
Bessone, F., Razori, M. V., & Roma, M. G. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 664
The past and present of serum aminotransferases and the future of liver injury biomarkers
McGill, M. R. (2016) · EXCLI journal · doi:10.17179/excli2016-800 · Cited by 488
Mitochondrial alterations in fatty liver diseases
Fromenty, B., & Roden, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.020 · Cited by 448
Self-citationDrug-induced liver injury: Interactions between drug properties and host factors
Chen, M., Suzuki, A., Borlak, J. T., Andrade, R. J., & Lucena, M. I. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.016 · Cited by 415
Metadata
- Authors
- Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A.
- Affiliations
- Inserm (FR)
- Corresponding author
- Pessayre, Dominique
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2012-01-30
- Volume
- 44
- Issue
- 1
- Pages
- 34-87
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2076781542
- Cited by
- 277
- References
- 604
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 11 · 2023: 21 · 2022: 22 · 2021: 31 · 2020: 16 · 2019: 15 · 2018: 26 · 2017: 19 · 2016: 21 · 2015: 26 · 2014: 23 · 2013: 13 · 2012: 2
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Metabolism Reviews (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- drug-induced liver injury, mitochondrial dysfunction, reactive drug metabolites, mitochondrial membrane disruption, oxidative phosphorylation, ATP synthase inhibition, mitochondrial DNA damage, lactic acidosis, hepatic steatosis, steatosis, lipid peroxidation, human leukocyte antigen, genetic susceptibility, drug safety testing
- MeSH terms
- DNA, Mitochondrial, Pharmaceutical Preparations, Fatty Liver, Humans, Immune System, Liver, Mitochondria, Liver, Oxidation-Reduction, Reactive Oxygen Species, Cell Respiration, Mitochondrial Proteins, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
